Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more

Recent & Breaking News (NDAQ:APLS)

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS

Business Wire July 18, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 18, 2023

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire July 18, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 17, 2023

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

GlobeNewswire July 10, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 6, 2023

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

GlobeNewswire June 7, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 6, 2023

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

GlobeNewswire May 25, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 5, 2023

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

GlobeNewswire May 4, 2023

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

GlobeNewswire May 3, 2023

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

GlobeNewswire April 27, 2023

Apellis Presents Phase 3 Functional Analyses of SYFOVRE(TM) (pegcetacoplan injection) for Geographic Atrophy

GlobeNewswire April 23, 2023

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

GlobeNewswire April 21, 2023

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won't Wait(TM) Campaign

GlobeNewswire April 17, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 6, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 6, 2023

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire March 1, 2023

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

GlobeNewswire February 27, 2023